| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The scrambled peptide does not have a specific biological target. It is used to control for non-specific effects (e.g., due to the peptide nature, charge, or solvent) that might be observed with the active LL-37 peptide.
|
|---|---|
| ln Vitro |
The scrambled LL-37 peptide is inactive. It is used as a negative control to validate that the effects observed with the active LL-37 peptide (e.g., antimicrobial activity, cytokine induction, cell migration) are specific to the LL-37 sequence and not due to non-specific peptide interactions.
|
| ln Vivo |
The scrambled peptide has no in vivo activity and is used as a negative control in animal studies to confirm that the effects of LL-37 are sequence-specific. It is co-administered in control groups.
|
| Enzyme Assay |
Non-cell binding assays are not performed for the scrambled peptide, as it is defined by its lack of activity. However, it can be used in MIC assays (see “cellular assays”) to demonstrate no antimicrobial effect.
|
| Cell Assay |
Cellular assays: The scrambled LL-37 peptide is used in all the same cellular assays as the active LL-37 peptide (see V76815-17), but at equivalent concentrations. For example, in a bacterial MIC assay, the scrambled peptide should show no inhibition of bacterial growth up to 128 ug/mL. In a wound healing scratch assay, the scrambled peptide should not promote cell migration. In a cytokine secretion assay, it should not induce cytokine release. Its lack of activity helps establish the specificity of the active peptide.
|
| Animal Protocol |
In vivo animal studies: The scrambled LL-37 peptide is used as a negative control in the same animal models as the active peptide (e.g., MRSA pneumonia model, wound healing model). Mice in the scrambled peptide control group receive the same dose and route of administration (e.g., intratracheal injection of 0.4-2.0 mg/kg). The scrambled peptide should not show any therapeutic effect (e.g., reduction in bacterial load, improvement in wound healing).
|
| ADME/Pharmacokinetics |
The scrambled peptide has similar physicochemical properties to the active peptide (MW ~4553 Da, solubility) but no activity. The acetate salt improves solubility. It is expected to have a short plasma half-life.
|
| Toxicity/Toxicokinetics |
The scrambled peptide is considered non-toxic at the concentrations used in research. It is used to control for any non-specific toxicities that might be observed with the active peptide.
|
| References |
[1]. Gerard Sheehan, et al. The Human Cathelicidin Antimicrobial Peptide LL-37 Promotes the Growth of the Pulmonary Pathogen Aspergillus fumigatus. Infect Immun. 2018 Jun 21;86(7):e00097-18.
|
| Additional Infomation |
The scrambled peptide is an essential tool for validating the specificity of LL-37 in research studies. It is used to demonstrate that the biological effects of the native LL-37 peptide are due to its specific sequence and not due to artifacts. The product is for research use only.
|
| Molecular Formula |
C205H340N60O53.C2H4O2
|
|---|---|
| Related CAS # |
LL-37 scrambled peptide
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
